↓ Skip to main content

Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: study protocol for a randomized controlled trial

Overview of attention for article published in Trials, March 2015
Altmetric Badge

Mentioned by

twitter
11 X users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: study protocol for a randomized controlled trial
Published in
Trials, March 2015
DOI 10.1186/s13063-015-0645-x
Pubmed ID
Authors

Zheng-tu Li, Li Li, Ting-ting Chen, Chu-yuan Li, De-qin Wang, Zi-feng Yang, Nan-shan Zhong

Abstract

Ban-Lan-Gen (BLG) is a traditional Chinese herbal medicine. It has been used for the prevention and treatment of virus-related respiratory diseases such as influenza virus infection. BLG contains some antiviral compounds, but few evidence-based clinical studies have been conducted to assess its efficacy against influenza. We assessed the effects of BLG (including efficacy and safety) on the treatment of seasonal influenza in an evidence-based clinical trial. We conducted a randomized, double-blinded, oseltamivir- and placebo-controlled, parallel-design clinical trial. A total of 177 subjects are going to be recruited after satisfying the criteria: (i) 18 to 65 years of age; (ii) illness onset within 36 h; (3) axillary temperature ≥38.0°C; and (iv) positive influenza (type A/B) virus test. Subjects will be assigned randomly into three groups in equal proportions: oseltamivir treatment, BLG granule treatment, and placebo treatment. Each group receives 5-day treatment and is followed up 1, 3, 5, 7 and 21 days later. Symptoms and patient compliance are recorded, and virus/serum viral antibodies tested. We will use the primary outcome, secondary outcome, and safety indicators to evaluate the efficacy and safety of BLG granules in the treatment of seasonal influenza. We have described the first clinical trial for treatment using a single herb against influenza A and B viruses in China. We will hold a large-scale clinical trial to comprehensively evaluate the effectiveness and safety of BLG against influenza infection based on the results of this pilot study. And this clinical trial will serve as an example for the study of other traditional herbal medicines in evidence-based clinical trials. This study has been registered at ClinicalTrials.gov: NCT02232945 (3 September 2014).

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 16%
Researcher 5 11%
Student > Postgraduate 3 7%
Lecturer 2 5%
Other 2 5%
Other 5 11%
Unknown 20 45%
Readers by discipline Count As %
Medicine and Dentistry 13 30%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Biochemistry, Genetics and Molecular Biology 2 5%
Business, Management and Accounting 1 2%
Agricultural and Biological Sciences 1 2%
Other 3 7%
Unknown 21 48%